Ovarian Cancer Survival Varies Widely Among Asian American Subgroups

[ad_1]

Ethnic-specific survival disparities among Asian American patients with ovarian cancer go unnoticed when the population is examined as a single group, according to a study published in Gynecologic Oncology.1

Past studies determined that ovarian cancer survival significantly varies across racial groups, with Asian Americans having the highest survival and Black Americans having the lowest. These disparities are likely due to a combination of factors, including differences in tumor characteristics, treatment, sociodemographic characteristics, and behaviors.

Asian Americans consist of numerous subgroups, with growing evidence showing the importance of disaggregating these groups when evaluating cancer mortality and survival. The researchers explained that some disparities may be missed if Asian Americans were examined as a single group. Categorizing Asian Americans as such is the usual approach when conducting ovarian cancer studies. However, whether their survival advantage is observed when each subgroup is examined separately is unknown.

So far, only a few studies disaggregated Asian American ethnic subgroups when evaluating ovarian cancer survival, resulting in conflicting findings. To clarify these results, the researchers conducted a disaggregated survival analysis of Asian American patients with ovarian cancer using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.2

The significant differences in ovarian cancer survival among Asian American subgroups emphasize the importance of analyzing these groups separately. | Image Credit: DragonImages – stock.adobe.com

They specifically used the November 2022 SEER Incidence Data with Census Tract Attributes database, which included patients diagnosed with cancer between January 1, 2006, and December 31, 2020, from 19 population-based cancer registries nationwide.1 Age-standardized 5-year cause-specific survival rates were calculated for patients with primary invasive ovarian cancer diagnosed between the ages of 20 and 84. They only analyzed non-Hispanic White patients and those from 7 Asian ethnic subgroups: Asian Indian/Pakistani, Chinese, Filipino, Hawaiian/Pacific Islander, Korean, Japanese, and Vietnamese.

Using a weighted approach, the researchers conducted multivariable Cox regression analyses to calculate average hazard ratios (AHRs) and 95% CIs to quantify the risk of ovarian cancer death among patients in each Asian ethnic subgroup vs non-Hispanic White patients.

Of the 68,129 patients with ovarian cancer analyzed, most were non-Hispanic White patients (n = 61,817). Conversely, of those belonging to Asian ethnic subgroups, most were Filipino (n = 1507), followed by Chinese (n = 1470), Asian Indian/Pakistani (n = 1280), Vietnamese (n = 580), Korean, Hawaiian/Pacific Islander (n = 464), and Japanese (n = 459).

The researchers discovered a statistically significant difference in mean age at diagnosis across all groups, with non-Hispanic White patients being diagnosed at an older age (61.39 years) than all Asian/Pacific Islander patients (P < .001). Among the Asian ethnic subgroups, Asian Indian/Pakistani patients were the youngest at diagnosis (53.77 years) and Japanese patients were the oldest (60.76 years; P < .001).

Also, a lower percentage of distant tumors was observed among all Asian ethnic subgroups vs non-Hispanic White patients (60.07%), with the lowest being among Vietnamese patients (48.10%; P < .001).

Apart from Hawaiian/Pacific Islanders, patients across all Asian ethnic subgroups had a higher overall 5-year survival rate than non-Hispanic White patients (47.90%); Asian Indian/Pakistani patients showed the highest survival rate (56.12%). However, Hawaiian/Pacific Islander patients were the only subgroup to demonstrate lower 5-year cause-specific survival than non-White Hispanic patients (44.99% vs 47.90%, respectively). Similarly, when considering tumor stage, the lowest 5-year survival was among Hawaiian/Pacific Islander patients with distant ovarian cancer (28.59%).

After adjusting for tumor, sociodemographic, and treatment characteristics, Asian Indian/Pakistani patients were 17% less likely to die from their disease than non-Hispanic White patients (adjusted hazard ratio [aHR], 0.83; 95% CI, 0.75-0.92). Conversely, Hawaiian/Pacific Islander patients were 28% more likely to die than non-Hispanic White patients (aHR, 1.28; 95% CI, 1.07-1.53). Other statistically significant factors associated with better survival included being diagnosed at a younger age and an earlier stage.

Lastly, the researchers acknowledged their limitations, including the limited information beyond basic sociodemographic, tumor, and treatment characteristics. Therefore, there are no available data on other factors impacting cancer outcomes, like comorbidities or behaviors. Despite their limitations, they emphasized the need for a disaggregated approach in future studies on Asian American patients with ovarian cancer.

“It is clear that more research is needed to uncover the behavioral and quality of care factors that likely play a role in ovarian cancer survivorship…” the authors concluded. “Only by taking a disaggregated approach when studying ovarian cancer among Asian Americans can future interventions be properly tailored to address this highly fatal disease.”

References

  1. Lee AW, Poynor V, Siddiqui S. Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020. Gynecol Oncol. Published online November 2, 2024. doi:10.1016/j.ygyno.2024.10.017
  2. Surveillance, Epidemiology, and End Results Program. National Cancer Institute. Accessed November 12, 2024. https://seer.cancer.gov/

[ad_2]

Source link

Trending Topics

Features

Download and distribute powerful vaccination QI resources for your community.

Sign up now to support health equity and sustainable health outcomes in your community.

MCED tests use a simple blood draw to screen for many kinds of cancer at once.

FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.

Discover an honest look at our Medicare system.

ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.

The single most important purpose of our healthcare system is to reduce patient risk for an acute event.

Related Posts
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks of Unregulated GLP-1 Drugs
Scroll to Top
Featured Articles
How NMQF Advances Minority Health Through Data, Research and Health Access
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks of Unregulated GLP-1 Drugs
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks o...
The Communities Most Burdened by Disease Should Be the First to Benefit from Artificial Intelligence
The Communities Most Burdened by Disease Should Be the First to Benefit from ...
Cancer Pain Care Access Gap Hits Black, Asian Patients
Black and Asian Cancer Patients Wait Longer for Pain Relief in New Study
What Is Cyclosporiasis Symptoms, Food Safety, and Reasons
What Is Cyclosporiasis? The Foodborne Illness Showing Up in the News
Categories
AI
ATTR-CM
BIPOC News
Cancer
Clinical Trials
Covid19
Diseases of the Body
Environment
Health Data
Health Equity Events
Health Policy
Health Tips
Subscribe to our newsletter to receive our latest news​
All Stories
How NMQF Advances Minority Health Through Data, Research and Health Access
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks of Unregulated GLP-1 Drugs
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks o...
BIPOC News
How NMQF Advances Minority Health Through Data, Research and Health Access
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
The Communities Most Burdened by Disease Should Be the First to Benefit from Artificial Intelligence
The Communities Most Burdened by Disease Should Be the First to Benefit from ...
Environment
UV Safety Awareness Month Raises Urgency on Skin Cancer Prevention and Sun Protection Equity
UV Safety Awareness Month Raises Urgency on Skin Cancer Prevention and Sun Pr...
Extreme Heat Safety Tips 5 Ways to Protect Your Health This Summer fyh.news
5 Heat Safety Tips That Could Protect Your Health This Summer
Lupus Awareness Event in Baltimore Aims to Support Research and Shine a Light on Health Disparities
Lupus Awareness Event in Baltimore Aims to Support Research and Shine a Light...
Work Force
A multigenerational Black and Hispanic family sitting together in a park, showing how Social Security helps support older adults, people with disabilities, and families across generations.
Millions of Older Americans Could Face Smaller Social Security Checks by 2032...
dreamstime_s_243253251
The Caregiver Journey: The Hidden Backbone of American Healthcare
Families gather at a Bronx community festival with live music, kids’ activities, and health booths sharing SOMOS social care resources and free screenings.
Celebrating Hispanic heritage while learning about health care

[xyz-ips snippet=”Output-Source-Name”]

Clinical Trials
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks of Unregulated GLP-1 Drugs
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks o...
Clinical Trial Diversity Remains a Critical Challenge in Alzheimer’s Research
Clinical Trial Diversity Remains a Critical Challenge in Alzheimer’s Research
Vaccines and Outbreaks
A parent checking a child's temperature during summer, illustrating the changing RSV patterns and year-round respiratory virus risks.
Can You Get RSV During the Summer?
Michelle Lam, MBA, of NYC Health + Hospitals/Elmhurst & Amy Harris of NYC Health + Hospitals/Elmhurst
Healthcare Leaders Spotlight Vaccine Equity and Adult Immunization Strategies...
Measles Outbreaks Surge: Essential Facts and Prevention Strategies
Measles Outbreaks Surge: Essential Facts and Prevention Strategies
Other Categories
AI
Read the latest AI News stories trending around the world
ATTR-CM
Cancer
Read the latest Cancer stories trending around the world
Covid19
Diseases of the Body
Read about the latest Diseases of the Body trending around the world
Friday Webinars
Every Friday, we bring you insightful webinars covering critical topics in healthcare, data equity, and policy reform.
Health Data
Read the latest Health Data stories trending around the world
Health Equity Events
Read the best Health Equity Events around the country.
Health Policy
Read the latest Health Policy stories trending around the world
Health Tips
Heart Health
Read the latest on Heart Health News, Stories and Tips.
kidney Health
Read more trending News about Kidney Health, Stories and Tips.